AU2016204834B2 — Combinations and modes of administration of therapeutic agents and combination therapy
Assigned to Abraxis Bioscience LLC · Expires 2018-10-04 · 8y expired
What this patent protects
The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may includ…
USPTO Abstract
The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime. WO 2006/089290 PCT/US2006/006167 A 200-Fig. I Control CAI 0.05 0.5 1 5 t0 ABI1-007 (n") Trrea tment !0007 nM Control 005 0.5 1 5 10 AfI-007 (M) Treanent
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.